About Bolder Science

Our mission is to provide healthcare professionals with unbiased clinical research information, easily.

Currently, you can access the following clinical trials being conducted worldwide:

359,057 studies
in
219 countries
Clinical trial information and results are updated daily from ClinicalTrials.gov. The latest data update was conducted on 01/21/2021.
This website is for US healthcare professionals

Log In to Bolder Science

or

Don't have an account? Sign Up

Please enter your email address.

You will receive a link to create a new password via email.

Log In

Create an Account

or
(optional) ?

Welcome, !

Please complete the following 4 questions to ensure you receive the information that best suits your needs.

Clinical Trials of Interest

When I’m looking for information on clinical trials, I usually am interested in...

finding clinical trials in which to enroll my patients

Rarely Often

finding newly launched clinical trials (for all phases)

Rarely Often

updates on status changes for clinical trials

Rarely Often

pipeline molecules

Rarely Often

Drug Interventions

Enter up to 3 drug interventions you are currently interested in:

Clinical trial information and results are updated daily from ClinicalTrials.gov. The latest data update was conducted on 01/21/2021.

FUlvestrant in Gynecological Cancers That Are Potentially Hormone Sensitive: the FUCHSia Study

Clinicaltrials.gov identifier NCT03926936

Recruitment Status Recruiting

First Posted April 25, 2019

Last update posted April 26, 2019

Study Description

Brief summary:

In this phase 2 clinical trial, the aim is to evaluate the efficacy of the ER-antagonist Fulvestrant in women with estrogen receptor positive (ER+) low grade gynecological cancers. The primary objective of the study is to determine the response rate (RR) upon Fulvestrant treatment, comprising either partial or complete response, as determined by RECIST v1.1 criteria for each tumor type. The secondary objectives are to: (1) determine progression-free survival (PFS) upon Fulvestrant treatment, after 3 years, in each tumor type group (2) assess clinical benefit (CB) upon Fulvestrant treatment, comprising complete response, partial response and stable disease, as determined by RECIST v1.1 criteria, in each tumor type group (3) assess duration of response in each tumor type group (4) assess safety and tolerability of Fulvestrant administration in each tumor type group (5) assess quality of life (QoL) and symptoms in each tumor type group. As exploratory objectives, the aim is to: (1) evaluate the feasibility of 16α-18F-fluoro-17β-estradiol (18F-FES) PET imaging for detection of ER expression (2) determine the value of sequential 18F-FES PET scans in predicting response to Fulvestrant (3) collect tumor biopsies and cf-DNA from patients enrolled in the trial. These samples will be subsequently characterized at the genetic level, to identify adaptive response mechanisms to Fulvestrant treatment.

  • Condition or Disease:Endometrial Cancer
    Leiomyosarcoma Uterus
    Sex Cord Stromal Tumor
    Serous Ovarian Tumor
    Endometrial Stromal Sarcoma
    Adenosarcoma of Uterus
  • Intervention/Treatment: Drug: Fulvestrant
  • Phase: Phase 2
Detailed Description

N/A

Study Design
  • Study Type: Interventional
  • Estimated Enrollment: 200 participants
  • Allocation: Non-Randomized
  • Intervention Model: Parallel Assignment
  • Masking: None (Open Label) ()
  • Primary Purpose: Treatment
  • Official Title: An Open-label, Single Arm, Prospective, Multi-center, Tandem Two Stage Designed, Phase II Study to Evaluate the Efficacy of Fulvestrant in Women With Recurrent/Metastatic Estrogen Receptor Positive Gynecological Malignancies
  • Actual Study Start Date: March 2019
  • Estimated Primary Completion Date: April 2022
  • Estimated Study Completion Date: December 2025
Arms and interventions
Arm Intervention/treatment
Experimental: Low-grade uterine sarcoma
Drug: Fulvestrant
intramuscular injection (2x 250mg), once every 2 weeks for the first month, and then monthly until completion of the study
Experimental: low-grade endometrial carcinoma
Drug: Fulvestrant
intramuscular injection (2x 250mg), once every 2 weeks for the first month, and then monthly until completion of the study
Experimental: low-grade serous ovarian cancer
Drug: Fulvestrant
intramuscular injection (2x 250mg), once every 2 weeks for the first month, and then monthly until completion of the study
Experimental: sex cord stromal tumors
Drug: Fulvestrant
intramuscular injection (2x 250mg), once every 2 weeks for the first month, and then monthly until completion of the study
Outcome Measures
  • Primary Outcome Measures: 1. Response rate [ Time Frame: week 24 ]
    partial or complete response, as determined by RECIST v1.1 criteria
  • Secondary Outcome Measures: 1. progression-free survival [ Time Frame: week 156 ]
    progression-free survival after 3 years
  • 2. clinical benefit [ Time Frame: week 24 ]
    Clinical benefit is defined as the number of patients having complete response, partial response or stable disease, as determined by RECIST v1.1 criteria
  • 3. duration of response [ Time Frame: up to week 156 ]
  • 4. number of participants with treatment-related adverse events as assessed by CTCAE v5.0 [ Time Frame: up to 56 days after stop study treatment ]
  • 5. EQ-5D quality of life assessment [ Time Frame: Quality of life questionnaires will be completed by the patients at baseline and thereafter 3-monthly up to week 156 ]
    Quality of life as measured by the EQ-5D questionnaire. EQ-5D has 2 parts—the EQ-5D descriptive system and the EQ visual analog scale (EQ VAS). The descriptive system comprises 5 health states (mobility, self-care, usual activities, pain/discomfort and anxiety/depression), which will be converted into a summary index according to the EQ-5D user guide. The EQ VAS records the self-rated health on an analog scale. For both EQ-5D index and EQ VAS, a higher score indicates a better health status. Descriptive statistics of the subscores and the summary score at each visit and the difference with baseline will be reported.
  • 6. EORTC QLQ-C30 quality of life assessment [ Time Frame: Quality of life questionnaires will be completed by the patients at baseline and thereafter 3-monthly up to week 156 ]
    Quality of life as measured by the EORTC-QLQ-C30 questionnaire. For EORTC QLQ-C30, functional scores (emotional, role, cognitive, physical, and social) will be pooled and a summary score will be calculated according to Giesinger et al. A higher score indicates better health for functioning and global health status, whereas for the symptom scales a lower score indicates a lower level of symptom burden. Descriptive statistics of the subscores and the summary score at each visit and the difference with baseline will be reported.
  • Other Outcome Measures: 1. Detection of ER expression by 18F-FES PET imaging [ Time Frame: up to week 156 ]
    16α-18F-fluoro-17β-estradiol (18F-FES) positron emission tomography (PET) technique uses a radiolabeled estrogen derivative and allows non-invasive, repetitive imaging of the ER receptor, mainly the α subtype. This technique has been validated for measurement of ER expression in breast cancer. PET parameters will be derived from the PET data at baseline and will be correlated to the treatment response and the survival of the patients (PFS and OS). Liver metastases will not be included in the analysis due to high physiologic background uptake.
  • 2. Predicting response to Fulvestrant by sequential 18F-FES PET imaging [ Time Frame: up to week 156 ]
    16α-18F-fluoro-17β-estradiol (18F-FES) positron emission tomography (PET) uses a radiolabeled estrogen derivative and allows non-invasive, repetitive imaging of the ER, mainly the α subtype. This technique has been validated for measurement of ER in breast cancer and it has been shown that lesions with no or limited reduction of 18F-FES uptake are at risk for early progression and thus therapy failure. The relationship between the absolute value of the PET parameters, and their change between baseline and Week 4, will be correlated to treatment response and survival of the patients. The hypothesis is that responding patients will have a median reduction of FES uptake on pre- and post-fulvestrant 18F-FES-PET (at Week 4) of >75% (based on SUVmax). All patients with CR or PR according to RECIST will be classified as having responded to Fulvestrant treatment. The response rate is hypothesized to be higher in the 18F-FES responder group than in the 18F-FES non-responder group.
  • 3. Genomic analysis of blood and tumor biopsies [ Time Frame: up to week 156 ]
    Core biopsies and blood from patients will be collected and stored in a biobank. cf-DNA will be isolated from plasma and copy number alterations will be measured by shallow whole-exome sequencing. DNA will be extracted form core biopsies and will be subject to ER/chromatin analysis, shallow whole-exome sequencing and targeted sequencing.
Eligibility Criteria
  • Ages Eligible for Study: 18 Years and older (Adult, Older Adult)
  • Sexes Eligible for Study: Female
  • Accepts Healthy Volunteers: No
Criteria

Inclusion Criteria:

- Written informed consent prior admission to the study

- Age ≥ 18 years at the moment of signing the informed consent

- Recurrent or metastatic low grade uterine sarcomas (low grade endometrial stromal
sarcoma, low grade adenosarcoma without sarcomatous overgrowth and low grade
leiomyosarcoma), low-grade endometrial carcinomas, sex cord stromal tumors (granulosa
cell tumors...) and low grade serous ovarian cancer

- Measurable disease, according to RECIST v1.1 criteria, assessed by CT scans

- ER-positive tumors based on immunohistochemistry, assessed using the Allred scoring
system (based on intensity and percentage of positive cells, see Appendix 4), and
archival tissue available

- At least and maximum of 1 prior line of hormonal therapy (tamoxifen, progestins and/or
aromatase inhibitors). Response on 1st line hormonal therapy must have lasted for at
least 3 months.

- Eastern Cooperative Oncology Group (ECOG) performance status: 0-2

- Demonstrate adequate organ function: platelets > 100 x 10E9/L, serum total bilirubin < 1.5x Upper Limit of Normal (ULN) (patients with confirmed Gilbert's syndrome may be included in the study), alanine transaminase or aspartate transaminase < 2.5x ULN if no demonstrable liver metastases or < 5x ULN in presence of liver metastases - Post-menopausal status as defined by (i) age 60 or more, or (ii) age 45-59 and satisfying the following criteria: amenorrhea for at least 12 months and FSH in postmenopausal range, or (iii) ≥ 18 years of age and having had a bilateral oophorectomy - Be willing to receive 18F-FES PET scan. Exceptions will be made in case of (i) patients living far from one of the imaging centers and for whom travelling would be a too high burden for their physical conditions; (ii) patients who received tamoxifen within 8 weeks prior to study Day 1. These patients will be enrolled, but they will not receive a FES PET scan - Be willing to donate a core tumor biopsy if technically feasible Exclusion Criteria: - Any other active malignancy or primary malignancy diagnosed within the previous 5 years, except for adequately treated squamous or basal cell carcinoma of the skin or in situ cervical carcinoma - Patients currently receiving (and unwilling to discontinue) any estrogen replacement therapy. - Patients participating in a study or having participated in a study of an investigational agent and received study therapy (or used an investigational device) within 4 weeks prior to study Day 1 - Patients who received prior chemo- or targeted therapy within 4 weeks prior to study Day 1 or who has not recovered from adverse events (i.e., adverse event not resolved to ≤ Grade 1 or baseline), due to a previously administered agent - Patients with no archival tissue available, except for patients from whom an additional fresh core biopsy can be obtained for ER assessment - Any other disease, metabolic dysfunction, physical examination or clinical laboratory finding that, in the investigator's opinion, gives reasonable suspicion of a disease or condition that contraindicates the use of an investigational drug, may affect the interpretation of the results, render the patient at high risk from treatment complications or interfere with obtaining informed consent. - Any condition not permitting compliance with the study protocol

Contacts and Locations
Contacts

Contact: Frédéric Amant, MD PhD +32 16 344273 frederic.amant@uzleuven.be

Contact: Sileny Han, MD PhD sileny.han@uzleuven.be

Locations

Belgium
UZ Antwerp
Edegem

Belgium
UZ Gent
Gent

Belgium
AZ Sint Maarten
Mechelen

Sponsors and Collaborators

Frederic Amant

Kom op tegen Kanker (Stand-up-to-Cancer), the Flemish cancer society

FWO Research Fund Flanders

Investigators

Principal Investigator: Frédéric Amant, MD PhD UZ Leuven

More Information
  • Responsible Party: Frederic Amant
  • ClinicalTrials.gov Identifier: NCT03926936 History of Changes
  • Other Study ID Numbers: S60857, 2017-005018-76
  • First Posted: April 25, 2019 Key Record Dates
  • Last Update Posted: April 26, 2019
  • Last Verified: April 2019
  • Individual Participant
    Data (IPD) Sharing
    Statement:
  • Plan to Share IPD: Yes
  • Supporting Materials: Study Protocol
  • Studies a U.S. FDA-regulated Drug Product: No
  • Studies a U.S. FDA-regulated Device Product: No
  • Product Manufactured in and Exported from the U.S.: Yes
  • Keywords provided by Frederic Amant: fulvestrant
    efficacy
    low-grade gynecological cancer
  • Additional relevant MeSH terms: Endometrial Neoplasms
    Leiomyosarcoma
    Sarcoma, Endometrial Stromal
    Sex Cord-Gonadal Stromal Tumors
    Adenosarcoma